pcn poster

Posters

Dosing and Treatment Patterns of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating dosing and treatment patterns with deutetrabena...

Andrew J. Cutler , MD;

10/26/2023

Dosing Intervals and Cost Per Day of Aripiprazole Once Every Month 400 mg and Aripiprazole Lauroxil 882 mg in the Treatment of Patients Diagnosed with Schizophrenia or Bipolar I Disorder

An updated claims database analysis of two formulations of the LAI aripiprazole, to evaluate the benefit of different dosing intervals to optimize the annual drug treatment costs among pa...

Soma S. Nag , PhD;

10/26/2023

Drug–Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

Valbenazine and deutetrabenazine product labeling both recommend dose adjustment for and/or avoidance of certain concomitant medications because of potential for drug–drug interactions (D...

Marko Mychaskiw , PhD;

10/26/2023

Early Use of Long-Acting Injectable Antipsychotics in Bipolar I Disorder: an Expert Consensus

Use of long-acting injectable antipsychotics (LAIs) for treatment of bipolar I disorder (BP-I) is limited to the severest cases, despite evidence showing their potential in treating early...

Murat Yildirim , MD, PhD;

10/26/2023

EEG Individual Alpha Frequencies May Improve Depression Symptoms in TMS Treatment

69 patients were grouped based on their baseline individual alpha frequency (IAF): 8, 9, 10, or 11 Hz. We show the percentage of patients in each group that reported a decrease, increase,...

Rachel Lian , BS;

10/26/2023

Effect of Adjunctive Cariprazine on Symptoms of Anhedonia in Patients with Major Depressive Disorder

Results from this post-hoc analysis suggest adjunctive cariprazine treatment may be effective for improving symptoms of anhedonia in patients with major depressive disorder.

Majid Kerolous , PharmD, MPH;

10/26/2023

Effectiveness of Vortioxetine in Elderly Patients With Major Depressive Disorder in Real-World Clinical Practice: Results From the RELIEVE Study

This subgroup analysis of the RELIEVE study evaluated effectiveness and tolerability of vortioxetine for treatment of major depressive disorder (MDD) in elderly patients. Elderly patients...

Michael Adair , MBChB;

10/26/2023

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder and Early-Stage Dementia: The MEMORY Study

The MEMORY study demonstrates the effectiveness of vortioxetine in clinically significantly improving depressive symptoms, cognitive performance, daily functioning, and HRQoL, as well as ...

Michael Adair , MBChB;

10/26/2023

Diagnosed Prevalence of Idiopathic Hypersomnia Among Adults in the United States

Idiopathic hypersomnia (IH) is a rare neurologic disorder characterized by excessive daytime sleepiness, sleep inertia, long and unrefreshing sleep/naps, and cognitive dysfunction. Sympho...

Jed Black , MD;

10/26/2023

Diagnosis and Symptoms of Narcolepsy from the Patient Perspective: Results from In-Depth Qualitative Interviews

This study used qualitative interviews to understand the patient experience of narcolepsy (types 1[NT1]=12 and 2 [NT2]=10). Many participants received a narcolepsy diagnosis at least 10 y...

Michael Doane , PhD;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products